Six Years, One Forged Prescription: How Ruti Aga Turned a Two-Year Case Into Career Death

On that March morning on a Chinese road, Ruti Aga won the half marathon. After the race, the Athletics Integrity Unit (AIU) collected a sample—a routine procedure at every label race. When the result came back, it contained methylprednisolone. This is not an anabolic steroid—it is a glucocorticoid, WADA Prohibited List class S9, prohibited only in-competition and only by injection, oral, or rectal routes. Which means if you take an injection for a knee injury a few days before a race and residues are still in your system during competition, you are in violation territory. But that same fact can be your defense—if you have real medical records, a real doctor, and a real TUE (Therapeutic Use Exemption) pathway. Ruti Aga had none of these. What she had was a forged prescription. According to the AIU statement released on Thursday, the 32-year-old Ethiopian marathoner has been banned for six years. The sanction is effective from 10 September—the same date she was provisionally suspended. The arithmetic is straightforward: two years for the presence violation, four years for tampering. Six total. But to understand this arithmetic, you have to hear the story of the prescription that became the pivot of the entire case. Aga's defense claimed she took the drug to treat a knee injury. The investigation found that the clinic that issued the prescription did not exist. The 'doctor' who wrote it was a family member with no medical registration. He claimed to have used 'an old prescription pad from a former workplace'—but the clinic explicitly stated no such pad was ever issued by them. Three independent verification failures. Not one held up. This case exposes a nuance in anti-doping law that media often misreads. The source report calls methylprednisolone a 'prohibited steroid'—technically incorrect. It is a glucocorticoid, and its use out-of-competition is entirely legal if a proper washout period is observed after injection. In my nine years of observation, this is the most common confusion in road-racing cases—athletes and their entourages do not understand that the drug is not 'wrong,' but the 'timing' is. If Aga had real medical records, she could have argued that this was therapeutic treatment, that the timing before the race was insufficient, and that she gained no advantage. But the forged prescription destroyed the one defense that could have worked. This is the same mistake seen in multiple East African road-racing cases: first a technical violation, then a larger violation added in the attempt to conceal it. Now look at the economic backdrop against which this case emerged. Aga won the 2026 Tokyo Marathon—a World Marathon Major title. She also has three second-place finishes at Major races. But after 2026, her racing pattern shifted: a few selected Major races, and appearances at Asian label races in between. This is a familiar model for East African marathoners—fewer races, higher appearance fees. China's label races are a major part of this model, because the fees are good and the competition level is reasonable. But these same races are now the AIU's highest-yield testing ground. Where the money is, the scrutiny follows. This collision is dangerous for athletes whose entourages treat medical procedures casually. And from here arises a larger question that has been overlooked in this case. A six-year ban for a glucocorticoid—a substance with no proven performance-enhancing effect on endurance. Is this sanction about the substance or about the tampering? The AIU's position is clear: the four-year sanction is not for the substance but for forging the prescription. But the question is whether this sanction is proportionate to the severity seen in other cases. AIU's rigor in East African road-racing cases is becoming a pattern—and that pattern deepens when the athlete lacks good legal representation. In Aga's case, a family member was the 'doctor'; no professional agent or medical team is visible. This is not an individual failure but a structural gap—for athletes who operate between Majors and label races, where medical support is often informal. Ethiopia's women's marathon depth is so extreme that even a 2:18 performer struggles for national team selection. Aga's absence will have no measurable impact on Ethiopia's medal capacity. But the question is not what Ethiopia lost—it is how many more Ruti Agas exist in that system, still relying on the same informal medical network. Until that network changes, such cases will keep coming. The ban is effective from 10 September. Aga is 32. In six years she will be 38—and in Ethiopian marathon depth, there is no place for a 38-year-old with a doping record. The ban is technically six years, but in practical terms it is the end of her career. A two-year sanction was possible. The six-year sanction came from the prescription she had made herself. For me, this case is a lesson: in anti-doping, more dangerous than the substance is the attempt to conceal it. And in that attempt, the first to drown is the one who starts it. The next time an athlete takes an injection for knee pain, the question should not be 'is this prohibited'—it should be 'do I have a real record of this.'